Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bleomycin + vinblastine + cisplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of bleomycin, vinblastine, and cisplatin—commonly referred to as PVB—is a multi-agent chemotherapy regimen primarily used in the treatment of advanced germ cell tumors, including testicular cancer and ovarian granulosa cell tumors. - **Bleomycin** is an antitumor antibiotic that induces DNA strand breaks through free radical formation. - **Vinblastine** is a vinca alkaloid that inhibits microtubule assembly, arresting cells in metaphase. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. This regimen has demonstrated efficacy in inducing complete responses in patients with metastatic germ cell neoplasms but is associated with significant hematologic and nonhematologic toxicities (notably pulmonary toxicity from bleomycin)[1][2][4][5][6]. The combination remains an important option for certain malignancies where curative intent is possible.
- Other names
- PVB
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on bleomycin + vinblastine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bleomycin + vinblastine + cisplatin.